Black technology, starting from daily check-in

Looking at Su Muxin who was holding up the picture scroll and looking fascinated, when Lin Yu was about to speak, the phone rang suddenly.

After taking a look, Lin Yu found that it was Ouyang Lei who called. Without thinking much, he connected directly.

In the next second, Ouyang Lei's familiar voice came from the other end of the phone: "Chairman, I have already arranged a professional team for tumor immunotherapy, and the topic of technology sharing has also been released, and I just need you to come here to teach the core technology gone."

Hearing the news, Lin Yu, who had just arrived home and didn't even sit on his buttocks, frowned, but he finally responded: "Well, okay, I'll be there later."

After hanging up the phone, Lin Yu couldn't help but glanced at Su Muyun, shrugged helplessly: "I have something to do with the company, I need to go, I guess I haven't come back for lunch."

"It's okay, you go, work is important." Su Muyun smiled softly, and immediately found that Lin Yu's coat was a little messy, so she walked up to him and gently smoothed out every wrinkle on his clothes.

At this time, no matter her expression, movement or expression, she was like a gentle and considerate wife waiting for her husband to come home.

Seeing this scene, Lin Yu couldn't help showing a warm smile on his face. He couldn't help lowering his head, and kissed Su Muyun's forehead: "I'm leaving."

"Um…"

Su Muyun nodded, and immediately watched Lin Yu disappear from sight at the door.

Seeing this, Su Muxin, who was holding a scroll beside her, couldn't help curling her lips, and her originally excited mood suddenly became speechless.

Good guy, you sprinkle dog food as soon as you come back, you really don't think of yourself as a human being.

Thinking of this, Su Muxin couldn't help but snorted softly, and immediately walked quickly towards her bedroom with the picture scroll and a lot of shopping bags in her arms.

After leaving home, Lin Yu drove straight to the immuno-oncology research and development center.

Along the way, what made Lin Yu speechless was that Zhao Yu, the director of the special intelligence bureau, called him suddenly, saying that they had completed the establishment of the company, and that the nanomechanical expert team was ready and waiting for him.

Hearing the news of this coincidence, Lin Yu hesitated for a while, and finally asked them to wait for the time being, until he was busy with the company's affairs.

There is no way, because compared to the manufacture of nano-holographic projectors, the company's cancer immunotherapy is obviously more urgent.

Moreover, according to Lin Yu's estimation, Xiaoyi's next course of treatment should start soon, but the second dose of neuroma antibody has not yet started.

Half an hour later, Lin Yu drove to the R&D center. Under Ouyang Lei's report, the two walked in together.

After a while, Lin Yu, who had learned about the situation, put on his white overalls and mask in the fitting room, and quickly entered the laboratory. Once again, he and the tumor immunology team who made the neuroma antibody with him last time skillfully performed the second neuroma Production of tumor antibodies.

It's just that this time is different from the last time. While making neuroma antibodies, Lin Yu also needs to teach the core technology to the people selected from the team.

However, what makes Lin Yu helpless is that although he speaks very clearly and in detail, because the core technology is too complicated, it is difficult for the other party to listen.

In fact, this is also normal, because the immunotherapy for neuroma was developed by Lin Yu based on the CAR-T cell technology rewarded by the system, combined with his own development of the super brain, the difficulty must be high.

In this regard, Lin Yu also thought of a way, which is to split the core technology into three parts and give them to three people to learn respectively, let them manufacture it first, and then combine the finished neuroma antibody.

And after the three of them have learned it, Lin Yu can let them split the core technology they have learned, let them be teachers, teach the next level of personnel, and finally realize the production line operation.

However, although Lin Yu's idea is beautiful, it is not so easy to practice.

Therefore, after making the second injection of neuroma antibody at night, Lin Yu found sadly that the first batch of three people who learned the core technology basically only understood about 5.00%.

Facing Lin Yu's helplessness, the three people who learned the core technology also blushed, and apologized to Lin Yu very embarrassed.

In fact, this can't be blamed on them, who makes people full of gaps between people.

For this situation, Lin Yu could only comfort the three of them and let them continue to practice, while he drove home.

In the following days, Lin Yu can be said to run back and forth between home and the company at two o'clock and one line every day.

However, Lin Yu was a little relieved that the speed and efficiency of the three people who learned the core technology continued to increase with the passage of time under his own teaching.

In the blink of an eye, half a month is fleeting.

At eleven o'clock on August 8th.

In the GMP laboratory, researchers wearing white masks and white overalls are tightly surrounded by the center of a laboratory table.

To be precise, they were surrounded by a special electronic device.

Soon, under the gaze of everyone, the rows of data on the display screen of the electronic instrument began to be refreshed continuously, and finally gradually froze.

Remissions such as neuroblastoma reduction.

Partial response rate: 85%

Complete remission rate: 89%

Overall response rate: 91%

Solid tumor and non-solid tumor control rate: 93%

Adverse reactions.

.........

"Hahahaha, the overall remission rate reached 91%, we succeeded!"

Looking at the data, the three researchers standing in front of the instrument shouted excitedly, and immediately hugged each other excitedly.

After hearing the news, the entire research team also applauded for them with smiles on their faces.

Compared with the excitement of everyone, Lin Yu, who was sitting not far away waiting for the result, finally breathed a sigh of relief after hearing the news, and even had a smile on his face.

After more than ten days, these three people finally managed to produce a neuroma antibody, which is really not easy.

After a moment of emotion, Lin Yu got up and walked over, and said with a smile: "The total remission rate has reached 91%, and it is only 4% away from the highest total remission rate. You are doing very well."

"Where, this is all the credit of the chairman. Without the careful guidance of the chairman, it would be impossible for us to make neuroma antibodies."

"That's right, the hardest part is actually the chairman. Not only did you develop the immunotherapy for neuroma, but you also spent time and effort teaching us yourself. Your contribution is the greatest."

"You're right, we're just standing on your shoulders, chairman, and that's nothing."

Facing Lin Yu's praise, the three people who learned the core technology looked solemn, looked at Lin Yu sincerely, and said from the bottom of their hearts.

"It's not that exaggerated."

Seeing this, Lin Yu just smiled and waved his hands: "Okay, the next thing will be left to you to solve. I only have one request, and that is to realize large-scale supply as soon as possible. Is it okay?"

"no problem!"